CarolynYungHoMD
Cardiology • Boston, MAEchocardiography, Cardiovascular Disease Genetics
Associate Professor of Medicine, Brigham and Women's Hospital
Dr. Ho is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
75 Francis St
Pbb 3
Boston, MA 02115Phone+1 617-732-7317- Is this information wrong?
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1998 - 2001
Harvard Medical SchoolClass of 1995
Certifications & Licensure
MA State Medical License 2000 - 2024- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Start of enrollment: 2006 Jan 01
- Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM Start of enrollment: 2014 Mar 01
- HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- A Customizable and Peer-Reviewed Curriculum for Cardiovascular Genetics and Genomics.C Anwar A Chahal, Dan M Roden, , Andrew P Landstrom, Carolyn Y Ho, Svati H Shah> ;Circulation. 2024 Mar 19
- Genetic Testing in Hypertrophic Cardiomyopathy.Ireland, C., Ho, C.> ;The American Journal of Cardiology. 2024 Feb 1
- 1 citationsAngiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials.Tino Severinsen, Jens Jakob Thune, Helga Lillian Gudmundsdottir, Christoffer Rasmus Vissing, Kasper Iversen, Carolyn Yung Ho, Henning Bundgaard, Anna Axelsson Raja> ;American Heart Journal. 2023 Dec 1
- Join now to see all
Lectures
- Circulating microRNAs as a Biomarker of Pediatric Hypertrophic Cardiomyopathy2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- The Future of HCM: new Diagnostic Tools and New Therapies2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyHarvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 10/13/2012
Authored Content
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
Press Mentions
Is Heart Disease Genetic?January 15th, 2021
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy PatientsMarch 30th, 2020
MAVERICK-HCM: Mavacamten Well Tolerated in Patients with Nonobstructive HCMMarch 30th, 2020- Join now to see all
Grant Support
- Using Genetics For Early Phenotyping &Prevention Of Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2010–2011
- Diagnostic And Treatment Strategies For Preclinical HCMNational Heart, Lung, And Blood Institute2005–2009
- Diastolic Function In Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2002–2003
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
